Dana-Farber Cancer Institute | Strategic Alliance Partners

Paul L. Nguyen, MD, discusses the role of radiation therapy in high-risk prostate cancer.

Today, we had the pleasure of sitting down with a group of experts in genitourinary cancers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Moffitt Cancer Center to discuss a malignancy that is not often an everyday focus: penile cancer.

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.

Quoc-Dien Trinh, MD, discusses ​the challenges of the novel coronavirus disease 2019 pandemic in prostate cancer. 

Quoc-Dien Trinh, MD, discusses surgical considerations for patients with prostate cancer in light of the novel coronavirus disease pandemic.

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

Ann H. Partridge, MD, MPH, discusses the role of genomic testing in breast cancer.

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Steven Lee Chang, MD, discusses the impact of the coronavirus disease 2019 on the surgical management of patients with genitourinary cancers.

Bradley A. McGregor, MD, sheds light on recently approved agents, as well as a multitude of novel therapies on the horizon, that appear to spell out a promising future for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Toni K. Choueiri, MD, discusses the novel coronavirus disease, which continues to impact the care of patients with metastatic renal cell carcinoma and other cancers in a multitude of ways.

David A. Reardon, MD, discusses the design of a phase 1/2 trial with INO-5401 and INO-9012 in glioblastoma.

Praful K. Ravi, MD, discusses the evolving treatment landscape of advanced bladder cancer.

Bradley McGregor, MD, discusses some of the recent approaches that have emerged in bladder cancer and renal cell carcinoma, as well as anticipated developments in each field.

David A. Reardon, MD, discusses the role of INO-5401 and INO-9012 in glioblastoma.

Guru P. Sonpavde, MD, discusses several trials in the field of first-line metastatic urothelial cancer that are testing combinations with gemcitabine/platinum-based therapy followed by maintenance avelumab.

Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.

Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.

Paul L. Nguyen, MD, discusses the role of radiation in high-risk prostate cancer and ongoing research efforts in the space.

Matthew S. Davids, MD, MMSc, discusses ​remaining questions with umbralisib plus ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma.

Praful K. Ravi, MD, discusses the emergence of immunotherapies, FGFR inhibitors, and antibody-drug conjugates and how they dramatically evolved the metastatic urothelial cancer treatment paradigm.

Savolitinib demonstrated encouraging efficacy and an improved safety profile over sunitinib in patients with MET-driven papillary renal cell carcinoma.

Toni K. Choueiri, MD, discusses current and emerging treatment options for patients with metastatic renal cell carcinoma.

Caron Jacobson, MD, discusses the initial ZUMA-5 findings and the next steps with axicabtagene ciloleucel in follicular lymphoma and marginal zone lymphoma.

Paul G. Richardson, MD, discusses the patient population analyzed in the first-in-human phase 1 trial of the CELMoD CC-92480.

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.

Mark M. Awad, MD, PhD, discusses the findings from the study, the importance of identifying patients with METex14 mutations, and the importance of understanding acquired resistance in NSCLC.

Caron Jacobson, MD, discusses the safety profile of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.